PolyModels Hub Secures $8.5M to Revolutionize Biopharma Process Development
November 24, 2025, 9:37 pm
PolyModels Hub, a London-based biotech firm, secures $8.5M in Series A funding. Molten Ventures led the round with Marathon Venture Capital. The funds boost its ModelFlow platform. ModelFlow accelerates drug development via AI and data. It aims to reduce experimentation and costs in biopharma.
London's PolyModels Hub just landed a significant investment. The biotech software company raised $8.5 million in Series A funding. Molten Ventures spearheaded the round, with Marathon Venture Capital also participating.
This funding marks a major step for PolyModels Hub. It plans to expand its engineering and product teams. Further development of its ModelFlow platform is also a priority. The goal is to reach a wider global pharmaceutical audience.
PolyModels Hub focuses on the digital transformation of biopharmaceutical process development. Its ModelFlow platform integrates AI, advanced modeling, and data-driven workflows. This helps pharmaceutical companies design, develop, and manufacture medicines more efficiently. The platform aims to drastically cut down on experimentation.
Traditional drug development is costly and time-consuming. It can cost billions to bring a new drug to market. A significant portion of that goes toward process development. PolyModels Hub aims to reduce these costs.
ModelFlow consolidates process knowledge, models, and workflow management. Scientists and engineers can design, test, and optimize drug processes faster. This reduces time, cost, and risk. It also improves quality and regulatory compliance.
The investment reflects growing confidence in biotech software. Several other companies in the sector have recently secured funding. These include ScienceMachine, Kiin Bio, Cellcolabs, and EnsiliTech. This collective funding underscores the increasing interest in digital innovation within the life sciences.
ModelFlow has already shown promising results. Early deployments have reportedly reduced experimental workloads by over 90%. Complex workflows that once required hundreds of experiments now require fewer than ten. This dramatic reduction significantly speeds up the development process.
Pharmaceutical companies recognize the strategic importance of process development. It is a key factor in achieving speed, quality, and regulatory success. As drug manufacturing becomes more complex, the need for scalable, data-driven solutions grows.
PolyModels Hub's ModelFlow offers a solution. It addresses the challenges of modern biopharma development. It empowers scientists with model-based tools. These tools enable them to transform molecules into medicines more efficiently.
Molten Ventures sees great potential in PolyModels Hub. The company combines deep domain expertise with cutting-edge technology. Their solution delivers value rapidly.
Marathon Venture Capital also expresses confidence in the company. PolyModels Hub redefines drug development processes. They leverage data and automation to accelerate innovation.
PolyModels Hub's platform facilitates collaboration across teams. It integrates data and expertise from different departments. This streamlined approach improves overall efficiency.
The company focuses on scalable solutions for process and regulatory workflows. This supports the broader digitalization of the biopharma industry. Ultimately, this contributes to faster delivery of new medicines to patients.
The $8.5 million in funding will help PolyModels Hub achieve its goals. The company will invest in its platform and its people. They are committed to revolutionizing biopharma process development.
"
PolyModels Hub Secures $8.5M to Revolutionize Biopharma Process Development
London's PolyModels Hub just landed a significant investment. The biotech software company raised $8.5 million in Series A funding. Molten Ventures spearheaded the round, with Marathon Venture Capital also participating.
This funding marks a major step for PolyModels Hub. It plans to expand its engineering and product teams. Further development of its ModelFlow platform is also a priority. The goal is to reach a wider global pharmaceutical audience.
PolyModels Hub focuses on the digital transformation of biopharmaceutical process development. Its ModelFlow platform integrates AI, advanced modeling, and data-driven workflows. This helps pharmaceutical companies design, develop, and manufacture medicines more efficiently. The platform aims to drastically cut down on experimentation.
Traditional drug development is costly and time-consuming. It can cost billions to bring a new drug to market. A significant portion of that goes toward process development. PolyModels Hub aims to reduce these costs.
ModelFlow consolidates process knowledge, models, and workflow management. Scientists and engineers can design, test, and optimize drug processes faster. This reduces time, cost, and risk. It also improves quality and regulatory compliance.
The investment reflects growing confidence in biotech software. Several other companies in the sector have recently secured funding. These include ScienceMachine, Kiin Bio, Cellcolabs, and EnsiliTech. This collective funding underscores the increasing interest in digital innovation within the life sciences.
ModelFlow has already shown promising results. Early deployments have reportedly reduced experimental workloads by over 90%. Complex workflows that once required hundreds of experiments now require fewer than ten. This dramatic reduction significantly speeds up the development process.
Pharmaceutical companies recognize the strategic importance of process development. It is a key factor in achieving speed, quality, and regulatory success. As drug manufacturing becomes more complex, the need for scalable, data-driven solutions grows.
PolyModels Hub's ModelFlow offers a solution. It addresses the challenges of modern biopharma development. It empowers scientists with model-based tools. These tools enable them to transform molecules into medicines more efficiently.
Molten Ventures sees great potential in PolyModels Hub. The company combines deep domain expertise with cutting-edge technology. Their solution delivers value rapidly.
Marathon Venture Capital also expresses confidence in the company. PolyModels Hub redefines drug development processes. They leverage data and automation to accelerate innovation.
PolyModels Hub's platform facilitates collaboration across teams. It integrates data and expertise from different departments. This streamlined approach improves overall efficiency.
The company focuses on scalable solutions for process and regulatory workflows. This supports the broader digitalization of the biopharma industry. Ultimately, this contributes to faster delivery of new medicines to patients.
The $8.5 million in funding will help PolyModels Hub achieve its goals. The company will invest in its platform and its people. They are committed to revolutionizing biopharma process development.
"